A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant Keytruda (pembrolizumab).
Results from the phase II TRUST-II trial demonstrate that taletrectinib, an investigational next-generation ROS1 inhibitor, shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 92% of patients with advanced ROS1-positive non-small cell lung cancer who had not previously been treated with a ROS1 tyrosine kinase inhibitor.
A study demonstrated that viral immune evasion enabled breakthrough infections of COVID-19 in patients with lung cancer, highlighting the importance of effective monitoring mechanisms, such as anti-N serology, to track infection rates in specific vulnerable populations.
Mount Sinai researchers have discovered a link between certain per- and polyfluoroalkyl substances and an increased risk for thyroid cancer, according to a study published in eBioMedicine.
Researchers at Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center uncovered racial bias leading to recommended therapy being rejected and to delays in care, diagnosis.
Cedars-Sinai Cancer investigators have identified two new treatment options for men with recurrent prostate cancer—both of which helped patients live longer without their disease progressing than the current standard treatment.
The phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine therapy compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer at a high risk of recurrence demonstrated long-term impact.
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy.
In the phase III CheckMate-77T trial evaluating the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo in patients with resectable stage 2A to 3B non-small cell lung cancer, the perioperative regimen showed a statistically significant and clinically meaningful improvement in the primary efficacy endpoint of event-free survival as assessed by Blinded Independent Central Review compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo.
